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Abstract
Introduction: To investigate whether accelerated hand bone mineral density (BMD) loss is associated with progressive 
joint damage in hands and feet in the first year of rheumatoid arthritis (RA) and whether it is an independent predictor 
of subsequent progressive total joint damage after 4 years.
Methods: In 256 recent-onset RA patients, baseline and 1-year hand BMD was measured in metacarpals 2-4 by digital 
X-ray radiogrammetry. Joint damage in hands and feet were scored in random order according to the Sharp-van der 
Heijde method at baseline and yearly up to 4 years.
Results: 68% of the patients had accelerated hand BMD loss (>-0.003 g/cm2) in the first year of RA. Hand BMD loss was 
associated with progressive joint damage after 1 year both in hands and feet with odds ratios (OR) (95% confidence 
intervals [CI]) of 5.3 (1.3-20.9) and 3.1 (1.0-9.7). In univariate analysis, hand BMD loss in the first year was a predictor of 
subsequent progressive total joint damage after 4 years with an OR (95% CI) of 3.1 (1.3-7.6). Multivariate analysis 
showed that only progressive joint damage in the first year and anti-citrullinated protein antibody positivity were 
independent predictors of long-term progressive joint damage.
Conclusions: In the first year of RA, accelerated hand BMD loss is associated with progressive joint damage in both 
hands and feet. Hand BMD loss in the first year of recent-onset RA predicts subsequent progressive total joint damage, 
however not independent of progressive joint damage in the first year.
Introduction
Bone damage in rheumatoid arthritis (RA) includes joint
damage and accelerated bone mineral density (BMD) loss
[1]. Joint damage is provoked by an increased osteoclast
and decreased osteoblast activation, leading to erosive
damage, and by proteolytic pathways, leading to cartilage
degradation. This is all mostly regulated by TNF-α, IL-1,
IL-6, IL-17 and receptor activator of nuclear factor kappa
B ligand (RANKL) [2-4]. It is believed that BMD loss,
both localized and generalized, is also primarily the effect
of increased osteoclast activity in RA [5]. In particular,
bones in the proximity of inflamed joints are susceptible
to BMD loss due to inflammation [6]. Furthermore, local-
ized hand BMD loss occurs in an early phase of RA [7]
and even in pre-RA undifferentiated arthritis [8], and
might precede erosive damage on X-ray [9,10].
Dual energy X-ray absorptiometry (DEXA) is the gold
standard for measuring BMD. Digital X-ray radiogram-
metry (DXR) was developed as a method of radiogram-
metry to estimate BMD in the metacarpals using
standard hand radiographs [11]. BMD measured by DXR
is highly correlated with DEXA measurements and DXR
has a high precision for detecting changes in BMD
[11,12]. Various clinical studies showed the association
between hand BMD loss measured by DXR and RA
severity, including disease activity, functional impairment
and joint destruction [6,13-22]. Two clinical studies, one
of them a pilot study, showed the potential value of BMD
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joint damage in hands [23,24]. However, to date, no data
are available on the association between hand BMD loss
and progressive joint damage in hands and feet and on
the value of hand BMD loss as predictor of joint destruc-
tion in recent-onset RA patients who are treated inten-
sively with disease modifying anti-rheumatic drugs
(DMARDs) and TNF-α inhibitors in a tight control set-
ting. We examined the association between accelerated
hand BMD loss and progressive joint damage in hands
and feet during the first year of recent-onset active RA to
see whether both types of bone damage have common
pathways in their pathogenesis, and we investigated
whether accelerated hand BMD loss in the first year of
RA was an independent predictor of subsequent progres-
sive joint damage after four years in patients who are
treated in a tight control setting.
Materials and methods
Patients
All measures were performed in the setting of the Behan-
del Strategieën (BeSt) study [25]. Patients aged 18 years
and older, who met the definition of RA as defined by the
American College of Rheumatology (ACR) 1987 revised
criteria, with symptom duration of less than two years
and active disease with 6 or more of 66 swollen joints and
6 or more of 68 tender joints and either an erythrocyte
sedimentation rate (ESR) of 28 mm/hour or more or a
visual analogue scale (VAS) global health of 20 mm or
more, and who were DMARD naïve, were included in the
trial from April 2000 to August 2002. Exclusion criteria
have been reported previously [25]. Of the 508 patients,
236 were excluded from this study predominantly due to
switch from analogue to digital radiographs. The other
272 patients had analogue radiographs at both baseline
and after one year and were eligible for this study. The
baseline and/or one year follow-up analogue radiographs
of 16 patients could not be analysed by DXR due to
underexposed images (13 patients) or improper position-
ing of the hands (3 patients). Hence, 256 patients were
included in the current study.
Study design
The BeSt study was conducted by rheumatologists partic-
ipating in the Foundation for Applied Rheumatology
Research, in 18 peripheral and 2 university hospitals in
the western part of the Netherlands. The medical ethics
committee at each participating center approved the
study protocol and all patients gave written informed
consent prior to participation in the study.
After inclusion, patients were randomized to be treated
according to one of four treatment strategies: sequential
monotherapy starting with methotrexate (MTX); step-up
combination therapy also starting with MTX; initial com-
bination therapy with quickly tapered high-dose predni-
sone, MTX and sulphasalazine, or initial combination
therapy with infliximab and MTX. For all groups, the
protocol described a number of subsequent treatment
steps for patients whose response to therapy was insuffi-
cient, based on the disease activity score (DAS) in 44
joints of more than 2.4. The treatment protocol and the
effect of the different treatment strategies on hand BMD
loss after one and two years are described earlier in detail
[6,25].
Concomitant treatment with non-steroidal anti-inflam-
matory drugs and intra-articular corticosteroids were
permitted but not parenteral corticosteroids. In case of
calcium intake of less than 1,000 mg/day and serum vita-
min D level below the local reference value at baseline,
suppletion of 500 to 1,000 mg/day calcium and 400 IE/
day vitamin D (colecalciferol), respectively, was advised.
Antiresorptive therapy with oral alendronate, 10 mg/day
or 70 mg/week, or risedronate, 5 mg/day or 35 mg/week,
was advised if the BMD measurement at baseline showed
at a T-score -2.5 standard deviations (SD) or less in the
spine and/or hip in non-corticosteroid users or a T-score
-1 SD or less in corticosteroids users (ACR recommenda-
tions) [6].
Hand BMD measurements
Analogue radiographs of both hands in the posterior-
anterior view were digitized by a high-resolution 300 DPI
scanner (Canon Vidar VXR-12 plus, Amstelveen, North-
Holland, The Netherlands) and analysed under blind con-
ditions using the DXR-online (Pronosco X-posure sys-
tem, Sectra, Sweden). According to the manufacturer,
there is a very good agreement between BMD measured
by DXR on original analogue radiographs and on digi-
talized versions. Patients who switched from analogue to
digital radiographs were excluded due to lack of compa-
rability between the different imaging devices.
DXR is a computerized version of the traditional tech-
nique of radiogrammetry originally proposed by Barnett
and Nordin [26]. The digitized hand radiograph is sub-
jected to a number of image processing algorithms to
measure the cortical thickness of three regions of interest
around the narrowest part of the second, third and fourth
metacarpal bones [11]. A mean surrogate BMD, based on
the mean volume per area, was calculated in g/cm2 with
correction for the estimated porosity. Both hands were
measured and the mean was used for the analyses.
Hand BMD loss after one year was categorized in two
groups using the cut-off of -0.003 g/cm2/year, equal to the
upper limit of normal BMD loss in the metacarpals
according to specifications by the manufacturer.
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Radiographic progression of joint damage in hands and
feet at baseline and after one to four years were indepen-
dently scored by two readers, blinded for patient charac-
teristics, treatment group and time order, using the
Sharp-van der Heijde score (SHS) [27]. The inter-class
correlation coefficient between the readers was 0.98. The
mean score of the two observers were used for the analy-
ses.
Progressive joint damage in the first year was defined as
an increase in total SHS of 5 units or more at year one
compared with baseline. In subanalyses, progressive joint
damage in hands was defined as delta SHS 0 to 1 year 5
units or more, whereas progressive joint damage in feet
was defined as delta SHS 0 to 1 year 3 units or more, due
to a 0.6 times lower maximum score in feet than in hands.
Subsequent progressive total joint damage in hands and
feet was defined as delta SHS 1 to 4 years 5 units or more.
Demographic and clinical variables
The following variables were collected at baseline: age;
sex; and symptom duration. At baseline and after one
year the following variables were collected: postmeno-
pausal status; body mass index (BMI); DAS; based on the
number of swollen joints and the Ritchie articular index
(RAI) for pain in tender joints; the VAS for patient's
global assessment of disease activity (0 to 100 mm); ESR;
C-reactive protein (CRP); serum IgM rheumatoid factor
(RF), defined as positive or negative according to locally
applied assays and cut-off units; and functional disability
by the Dutch validated health assessment questionnaire
(HAQ). The presence of anti-citrullinated protein anti-
bodies (ACPA) was determined from serum samples
obtained at baseline or during follow up. The presence or
absence of ACPA is a stable characteristic [28].
Statistical analyses
All analyses were performed in an intention-to-treat
method using all available data.
To determine the associations between hand BMD loss
and progressive joint damage in hands and feet after one
year, multivariate logistic regression analyses were per-
formed adjusted for age, gender, postmenopausal status,
BMI, HAQ, baseline SHS, treatment group, and the use of
intra-articular steroids and antiresorptive drugs (bisphos-
phonates, vitamin D and calcium supplements and hor-
mone replacement therapy (HRT)).
The sensitivity, specificity, and positive and negative
predictive value of hand BMD loss with regard to total
progressive joint damage in the first year were calculated.
Various baseline demographic and disease-related factors
and one-year follow-up disease-related factors were anal-
ysed regarding prediction of subsequent progressive total
joint damage after four years by univariate logistic regres-
sion analyses adjusted for age, gender, postmenopausal
status, BMI and HAQ, and additionally adjusted for the
treatment group and use of antiresorptive drugs and
intra-articular steroids during the first year follow-up in
case of one-year follow up variables. The following fac-
tors were analysed: baseline demographic factors (gender,
age ≥ 50 years, postmenopausal status and BMI ≥ 25 kg/
m2), baseline disease-related factors (symptom duration ≥
6 months, presence ACPA and RF, number of swollen
joints ≥ 10, RAI ≥ 10, ESR ≥ 30 mm/hr, CRP ≥ 10 mg/L,
HAQ ≥ 1.057 units [29] and SHS ≥ 1 unit) and one-year
follow-up disease-related factors (high area under the
curve (AUC) of number of swollen joints, RAI, ESR and
CRP and delta HAQ ≤ -0.22 units [30], total SHS ≥ 5 units
and hand BMD loss >-0.003 g/cm2). Both significant (p-
value < 0.05) and borderline significant (0.05<P < 0.10)
predictors derived by these univariate analyses were
entered in multiple multivariate logistic regression analy-
ses to determine the independent predictors of subse-
quent progressive joint damage.
Results
Patient characteristics
The baseline characteristics of the 256 patients included
in the study and 252 patients excluded are shown in Table
1. Patients included had shorter disease duration, were
less frequently ACPA positive and had less damage in the
feet, especially less cartilage degradation, compared with
the non-included patients. With regard to randomization
into the four treatment groups by age, sex, RF, DAS, ESR
level, CRP level, HAQ score, hand SHS and BMD
(obtained in 107 patients at baseline who were excluded
from this study), there were no significant differences
between patients who were enrolled in this study and
who were not.
Of the study population, 65% were females, 66% of
them postmenopausal, and the mean age was 54 years. At
baseline the patients had a median symptom duration of
24 weeks and mean (SD) DAS of 4.4 (0.9). RF was positive
in 62% of the patients and 70% had at least one erosion in
hands and feet.
Changes in hand BMD and joint damage in hands and feet 
in the first year
The median (interquartile range (IQR)) hand BMD
change was, in absolute value, -0.0088 g/cm2 (-0.021 to -
0.0005) and in percentage of baseline BMD -1.4% (-3.8%
to -0.1%) after one year. On the individual level, 68% of
patients had accelerated hand BMD loss of more than -
0.003 g/cm2, from now on called hand BMD loss. The
mean (SD) progression of total SHS in hands and feet,
and SHS in hands and feet separately was 3.0 (11.3), 1.9
(7.0) and 1.1 (5.0), respectively. After one year 18%, 12%
and 11% of the patients had progressive total joint dam-
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Table 1: Baseline demographic and disease characteristics from patients from the BeSt cohort who are included and not 
included in this study
Demographic variables Patients included in study 
(n = 256)
Patients not included in study 
(n = 252)
P value
Age, years† 54 (14) 54 (13) 0.941
Women, % 65 70 0.208
Postmenopausal, % 66 68 0.817
Randomization between the 
treatment groups, %
Sequential monotherapy: 25
Step-up therapy: 23
Initial combi therapy with 
prednisone: 27
Initial combi therapy with 
infliximab: 26
Sequential monotherapy: 25
Step-up therapy: 25
Initial combi therapy with 
prednisone: 25
Initial combi therapy with 
infliximab: 25
0.921
Disease related variables
Symptom duration, weeks‡ 24 (14-53) 23 (13-53) 0.929
Disease duration, weeks‡ 2 (1-5) 3 (1-5) 0.011
ACPA positive, %, n = 247 (not all 
baseline)
54 70 0.000
RF positive, % 62 68 0.175
DAS† 4.4 (0.9) 4.4 (0.9) 0.529
ESR‡ 37 (19-54) 36 (19-57) 0.781
CRP‡ 20 (9-58) 26 (10-55) 0.272
HAQ score, 0-3 scale† 1.4 (0.6) 1.4 (0.7) 0.276
Total SHS, 0-448 scale‡, † n = 248 5.9 (8.2)/2.5 (0.5-8.5) 8.7 (12.7)/4.3 (1.0-11.0) 0.024*
Erosion score, 0-280 scale‡, † 2.8 (4.7)/1 (0.0-3.5) 3.9 (6.2)/1.5 (0.0-5.0) 0.011*
JSN score, 0-168 scale‡, † 3.0 (4.8)/1.0 (0.0-4.1) 4.8 (7.7)/2.0 (0.0-5.6) 0.041*
Total SHS hands, 0-280 scale‡, † 3.0 (4.8)/1.0 (0.0-3.5) 4.6 (8.4)/1.0 (0.0-5.0) 0.217*
Erosion score hands, 0-160 scale‡, † 0.9 (1.8)/0.0 (0.0-1.0) 1.4 (3.1)/0.5 (0.0-1.0) 0.112*
JSN score hands, 0-120 scale‡, † 2.1 (3.9)/0.0 (0.0-3.0) 3.1 (6.0)/0.50 (0.0-3.6) 0.247*
Total SHS feet, 0-168 scale‡, † 2.8 (5.4)/0.5 (0.0-3.0) 4.1 (7.2)/1.5 (0.0-4.5) 0.011*
Erosion score feet, 0-120 scale‡, † 1.9 (3.9)/0.5 (0.0-2.0) 2.5 (4.6)/0.5 (0.0-2.5) 0.123*
JSN score feet, 0-48 scale‡, † 0.9 (2.0)/0.0 (0.0-1.0) 1.7 (3.4)/0.0 (0.0-2.0) 0.013*
Presence erosive damage ≥ 1 unit, 70 74 0.321
% n = 248 28 34 0.166
Presence erosive damage hands ≥ 1 
unit, %
40 46 0.205
Presence erosive damage feet ≥ 1 
unit, %
Hand BMD (g/cm2)† 0.59 (0.08) 0.59 (0.09) n = 107 0.870
†Mean (standard deviation); ‡ median (interquartile range); * P values derived from non-parametric tests.
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte 
sedimentation rate; HAQ, health assessment questionnaire; JSN, joint space narrowing; RF, rheumatoid factor; SHS, Sharp-van der Heijde 
score.
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and feet joint damage of 3 units or more, respectively.
In patients with hand BMD loss the mean (SD) progres-
sion of total SHS after one year was 4.0 (13.6) compared
with 1.1 (2.6) in patients without hand BMD loss (P =
0.036 derived by non-parametric test). Hand BMD loss
after one year was significantly associated with higher
progression rates both in hands (2.5 (8.4) versus 0.8 (1.7),
P = 0.033) and feet (1.4 (5.9) versus 0.4 (1.5), P = 0.047).
The cumulative probability plots of changes in total SHS
and changes in hands and feet SHS separately after one
year in patients with and without hand BMD loss are
shown in Figure 1. Multivariate logistic regression analy-
ses adjusted for possible confounders were performed to
study the independent associations between hand BMD
loss and progressive total joint damage in hands and feet.
Progressive total joint damage in hands and feet after one
year was independently associated with hand BMD loss
with an odds ratio (OR) (95% confidence interval (CI)) of
10.6 (2.6 to 42.7; P = 0.001). In separate analyses, hand
BMD loss was associated with progressive joint damage
in both hands and feet after one year, although more
strongly in hands (OR (95% CI) 5.3 (1.3 to 20.9)) than in
feet (3.1 (1.0 to 9.7)). Both erosion and joint space nar-
rowing (JSN) score in hands and feet contributed equally
to the association with hand BMD loss (data not shown).
Sensitivity, specificity and predictive value of hand BMD 
loss in the first year
The sensitivity of hand BMD loss for detecting progres-
sive total joint damage after one year was 39 of 45 (87%)
and the specificity 74 of 203 (36%). The positive predic-
tive value, the probability of the presence of progressive
joint damage when hand BMD loss is present, was 39 of
168 (23%), whereas the negative predictive value, the
probability of absence of progressive joint damage when
hand BMD loss is absent, was 74 of 80 (93%).
Predictors of subsequent progressive radiographic damage 
after four years
The mean (SD) cumulative progression of total SHS in
hands and feet was 3.0 (11.3), 4.9 (14.5), 5.8 (16.7) and 6.6
(13.3) after one to four years compared with baseline.
After one to four years, 18%, 26%, 27% and 30% of the
patients, respectively, had progressive total joint damage
of 5 units or more. The association between hand BMD
loss in the first year and progressive total joint damage
remained over time up to four years (Figure 2).
The mean (SD) progression of total SHS was 2.9 (7.6)
after four years compared with year one and 14% of the
patients had progressive total joint damage of 5 units or
more after four years compared with year one. To investi-
gate whether hand BMD loss in the first year could pre-
dict long-term damage progression, univariate logistic
regression analyses were performed with subsequent pro-
gressive total joint damage after four years of 5 units or
more compared with year one as dependent variable and
various potential baseline and one year follow-up predic-
tors as independent variables adjusted for possible con-
founders (Table 2). Of the baseline variables, the presence
of ACPA, RF and joint damage at baseline were signifi-
cant predictors of subsequent progressive total joint
damage after four years. Of the one-year follow-up vari-
ables, a high AUC of ESR and CRP, progressive total joint
damage of 5 units or more and hand BMD loss were sig-
nificant predictors of subsequent progressive joint dam-
age after four years. The association of hand BMD loss
with subsequent progressive joint damage was less strong
(OR (95% CI) 3.1 (1.3 to 7.6)) than the association with
progressive joint damage in the first year (OR (95% CI)
30.7 (9.4 to 100)).
Multiple multivariate regression analyses were per-
formed to investigate the predictive ability of different
factors and the mutual interaction between them. In the
first multivariate model, all (borderline) significant pre-
dictors from the univariate analyses were entered,
adjusted for possible confounders (Table 3). The presence
of ACPA was an independent predictor of progressive
joint damage with an OR (95% CI) of 3.1 (1.4 to 6.1). Pro-
gressive joint damage in the first year was a strong and
independent predictor of subsequent progressive joint
damage with an OR (95% CI) of 27.1 (10.9 to 67.4). Hand
BMD loss in the first year with the diagnosis of RA was
not an independent predictor anymore (P = 0.688). The
adjusted R2, estimating the proportion of variance in pro-
gressive joint damage that is explained by the predictors,
was 0.53.
In the second multivariate model all (borderline) signif-
icant predictors from the univariate analyses were
entered, except progressive joint damage in the first year,
adjusted for possible confounders (Table 4). Hand BMD
loss in the first year was a predictor of subsequent pro-
gressive joint damage independent of the presence of
auto-antibodies, joint damage at baseline and high AUC
of ESR and CRP with an OR (95% CI) of 3.0 (1.1 to 8.8).
The adjusted R2 was considerably lower at 0.29.
To explore further the usefulness of progressive joint
damage in the first year as a predictor of subsequent pro-
gressive damage, joint damage progression in the first
year was divided in to four groups: no progression (SHS ≤
0 unit, the reference group), dubious progression
(0<SHS<5 units), moderate progression (5 ≤ SHS<10
units) and high progression (SHS ≥ 10 units). They were
then entered in a third multivariate regression analysis
together with all (borderline) significant predictors from
the univariate analyses and possible confounders. This
analysis showed that even dubious progressive joint dam-
age was an independent predictor of subsequent progres-
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and that the ORs (95% CIs) were considerably higher
when the progressive joint damage in the first year was
moderate, 68 (14 to 345), or high, 144 (20 to 1045).
Discussion
This study into the association between hand BMD loss
and radiographic joint damage progression shows that in
the first year of RA hand BMD loss is associated with pro-
gressive joint damage in hands and feet, and that the
association seems stronger with damage in hands than in
feet. Moreover, hand BMD loss in the first year predicts
subsequent progressive total joint damage: however, not
independent of progressive joint damage in the first year.
The relation between BMD loss and progressive joint
damage in the first year of RA suggests that both types of
bone damage share common pathways in their pathogen-
esis and are the result of the same inflammatory process.
It is thought that BMD loss in RA patients is caused, just
like joint damage, by increased osteoclast activation,
mainly regulated by TNF-α, IL-1, IL-6, IL-17 and RANKL
[2,3]. This is also in line with in vitro studies showing
increased osteoclast functional activity in RA patients
with generalized osteopenia [5]. A stronger association
between hand BMD loss and progressive joint damage in
hands compared with damage in feet also suggests that
bones in the direct proximity of the inflammatory activity
are more susceptible to BMD loss due to, besides the sys-
temic, the local effect of high pro-inflammatory cytokine
levels originating in adjacent active arthritis of the hand
joints. On the other hand, it may also be partially
explained by methodological issues. Firstly, less joint
damage in feet can be detected due to less evaluated
Figure 1 Cumulative probability plot of changes in Sharp-van der 
Heijde score (SHS). Results are shown in both hands and feet, in only 
hands and in only feet after one year in recent-onset active rheumatoid 
arthritis patients with accelerated hand bone mineral density (BMD) 
loss (triangles) and without accelerated hand BMD loss (circles) after 
one year.
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Figure 2 Mean progression of total Sharp-van der Heijde (SHS) in 
hands and feet after up to four years in patients with (black col-
umns) and without (white columns) hand bone mineral density 
(BMD) loss in the first year of rheumatoid arthritis. The differences 
in mean total SHS progression after one, two, three and four years be-
tween patients with and without hand BMD loss in the first year are all 
significant (P < 0.05 derived by non-parametric tests).
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used a lower cut-off point to define progressive damage
in feet (3 units in feet versus 5 units in hands due to 0.6
times lower maximum score in feet) and after this correc-
tion the percentages of patients having progressive joint
damage in the hands and in feet were similar. Secondly,
the patients in this subanalysis had significant less dam-
age in the feet than the patients who were excluded from
this subanalysis; however, in absolute terms, our popula-
tion had active disease with high DAS and erosions pres-
ent in the majority of patients at baseline.
In the first year of RA, hand BMD loss was seen in 68%
of the patients, whereas progressive joint damage was
seen in only 18%. There are several explanations for this
disassociation. First, localized BMD loss occurs mostly
earlier in and more often during the disease course than
advanced joint damage to bone and cartilage, especially
in recent-onset RA [9,10]. This is emphasized by the sen-
Table 2: Baseline and one-year follow-up predictors of subsequent progressive total joint damage in hands and feet after 
four years derived from univariate logistic regression analyses
Progressive total joint damage 1-4 ≥ 5 units
β OR (95% CI) P value
Baseline variables
Female gender -0.28 0.76 (0.38-1.49) 0.418
Age ≥ 50 years -0.11 0.90 (0.47-1.71) 0.744
Postmenopausal status 0.56 1.75 (0.70-4.40) 0.232
BMI ≥ 25 kg/m2 -0.54 0.58 (0.31-1.11) 0.100
Symptom duration ≥ 6 
months
-0.02 0.98 (0.52-1.87) 0.958
Presence ACPA 1.57 4.80 (1.39-16.6) 0.001
Presence RF 1.14 3.11 (1.43-6.78) 0.004
Number of swollen joints ≥ 10 -0.42 0.66 (0.32-1.33) 0.243
Ritchie articular index ≥ 10 -0.39 0.68(0.34-1.36) 0.276
ESR ≥ 30 mm/hr 0.12 1.13 (0.59-2.18) 0.714
CRP ≥ 10 mg/L 0.63 1.88 (0.82-4.31) 0.136
HAQ ≥ 1.057 units -0.39 0.67 (0.35-1.30) 0.240
SHS ≥ 1 unit 1.99 7.29 (1.70-31.14) 0.007
First year follow-up 
variables
High AUC number of swollen 
joints
-0.002 0.998 (0.991-1.006) 0.692
High AUC Ritchie articular 
index
-0.003 0.997 (0.992-1.003) 0.325
High AUC ESR 0.002 1.002 (1.001-1.004) 0.003
High AUC CRP 0.003 1.003 (1.001-1.004) 0.000
Delta HAQ ≤ -0.22 units 0.273 1.31 (0.56-3.09) 0.531
Progressive SHS ≥ 5 units 3.42 30.7 (9.4-100.1) 0.000
Hand BMD loss >0.003 g/cm2 1.15 3.14 (1.30-7.57) 0.011
All variables are adjusted for age, gender, postmenopausal status, BMI and HAQ. First follow-up variables are additionally adjusted for 
treatment group and the use of intraarticular corticosteroids injections and anti-resorptive therapy (bisphosphonates, calcium and vitamin 
D suppletion and hormone replacement therapy).
ACPA, anti-citrullinated protein antibodies; AUC, area under the curve; BMD, bone mineral density; BMI, body mass index; CI, confidence 
interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; OR, odds ratio; RF, rheumatoid 
factor; SHS, Sharp-van der Heijde score.
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Page 8 of 11sitivity, specificity and predictive value of hand BMD loss
with regard to progressive joint damage in the first year.
Both the sensitivity and negative predictive value were
high, 87% and 93%, respectively, whereas the specificity
and positive predictive value were low, 36% and 23%,
respectively, suggesting that most patients with progres-
sive joint damage also have hand BMD loss at the same
time, whereas in most patients with hand BMD loss pro-
gressive joint damage is absent. A second explanation
might be that the technique of measurement of BMD loss
by DXR is more sensitive to detect significant changes in
cortical BMD during a follow-up period, while progres-
sive joint damage as measured by the semi-objective SHS
method is less sensitive to detect significant changes in
structural damage, both erosions and JSN, during the
same follow-up period.
We showed that hand BMD loss in the first year of RA
is a predictor of subsequent progressive total joint dam-
age, independent of the presence of auto-antibodies and
joint damage at baseline. This is in accordance with the
findings of Hoff and colleagues, who in RA patients with
mean disease duration of 2.2 years at inclusion also
showed that hand BMD loss was a predictor of progres-
sive damage in hands after 5 and 10 years, independent of
baseline predictors, such as joint damage at baseline and
the presence of ACPA [24]. However, hand BMD loss is
probably predicting progressive joint damage because
hand BMD loss itself incorporates the effect of inflamma-
tion over time, as opposed to other factors that are static
measures of the situation at baseline. Therefore we com-
pared the predictive value of hand BMD loss with
changes in other potential one-year follow-up predictors
in multivariate regression analyses, and found that radio-
graphic progressive joint damage is a much stronger pre-
dictor for subsequent progressive damage and that hand
BMD loss was not predicting subsequent progressive
damage independent of progressive damage in the first
year probably due to the common inflammatory pathway
between BMD loss and joint damage.
As progressive joint damage in the first year is superior
as a predictor of further joint damage progression, in
daily practice hand BMD loss after one year will not add
to the identification of patients at risk for further destruc-
tion in recent-onset active RA. However, as hand BMD
measurements by DXR are highly precise in detecting
changes [12], early BMD evaluation, at three to four
months after disease onset or even in the undifferentiated
stage of the disease, might be a useful tool to predict poor
outcome in these patients.
It might be argued whether progression of SHS is useful
in clinical practice as a predictor, because it is a compli-
cated scoring method that requires special training to
perform. To mimic the daily clinical practice of radio-
graphic assessment, we categorized the progression of
Table 3: Baseline and one-year follow-up predictors of subsequent progressive total joint damage in hands and feet after 
four years derived from multivariate logistic regression analysis
Progressive total joint damage 1-4 ≥ 5 units
β OR (95% CI) P value
Baseline variables
Presence ACPA 1.20 3.14 (1.37-6.12) 0.015
Presence RF 0.59 1.80 (0.55-6.08) 0.314
SHS ≥ 1 unit 0.85 2.55 (0.48-13.0) 0.342
First year follow-up 
variables
High AUC ESR 0.001 1.001 (0.998-1.004) 0.444
High AUC CRP 0.001 1.001 (0.999-1.004) 0.339
Progressive SHS ≥ 5 units 3.35 27.1 (10.9-67.4) 0.000
Hand BMD loss >0.003 g/cm2 0.30 1.30 (0.38-3.84) 0.688
R2, adjusted 0.534
All variables with a P < 0.10 in the univariate analyses were entered in this multivariate analysis corrected for age, gender, postmenopausal 
status, BMI and health assessment questionnaire and first year follow-up variables additionally corrected for the use of anti-resorptive 
therapy (bisphosphonates, calcium and vitamin D suppletion and hormone replacement therapy) and intraarticular corticosteroid injections 
during first year and treatment group during.
ACPA, anti-citrullinated protein antibodies; AUC, area under the curve; BMD, bone mineral density; BMI, body mass index; CI, confidence 
interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; OR, odds ratio; RF, rheumatoid factor; SHS, Sharp-van der Heijde score.
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Page 9 of 11joint damage in four categories: patients with no, dubi-
ous, moderate or high progression. We found that even
patients with dubious progressive damage in the first year
had 5-fold more subsequent progressive damage, and
with moderate and high progression even 65-fold and
138-fold more than patients with no progression, while
hand BMD loss was associated with 3-fold more subse-
quent damage. Furthermore hand BMD loss measured by
the DXR technology also requires special equipment, in
general not available in medical centers, or payments for
the measurements when the online service is used.
Further the fact that there are significant differences in
baseline variables between patients who were included in
this trial and patients who were not included might be
argued. The included patients have shorter disease dura-
tion, are less often ACPA positive and have less joint
damage at baseline, suggesting that patients with rela-
tively less active disease were included in this trial. Nev-
ertheless, in absolute terms, the included patients had
high disease activity with erosive damage in the majority,
even in this early stage of the disease.
Conclusions
In the first year of RA, accelerated hand BMD loss is asso-
ciated with progressive joint damage in both hands and
feet. Hand BMD loss in the first year is a predictor of sub-
sequent progressive total joint damage; however, it is not
independent of progressive joint damage in the first year,
which remains the strongest predictor of subsequent
damage. These findings suggest that both methods detect
effects in a common pathway of osteoclastic activity and
that initial joint damage progression in the first year of
RA is superior in predicting later progressive joint dam-
age.
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